

HARVARD BIOSCIENCE INC  
Form 8-K  
February 25, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **February 25, 2011**

**HARVARD BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33957**  
(Commission File Number)

**04-3306140**  
(IRS Employer Identification No.)

**84 October Hill Road, Holliston, MA**  
(Address of principal executive offices) **01746**  
(Zip Code)  
Registrant's telephone number, including area code: **(508) 893-8999**

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 2.02. Results of Operations and Financial Condition.**

On February 25, 2011, Harvard Bioscience, Inc., (the "Company") issued a press release announcing financial results for the three months and year ended December 31, 2010. Since issuing the press release, it has come to the Company's attention that two figures in Exhibit 2 of the

Edgar Filing: HARVARD BIOSCIENCE INC - Form 8-K

release were inadvertently transposed. The "Income from continuing operations" and "Net income" figures for the Year Ended December 31, 2010, should have been \$19,015 not \$19,105. The corrected press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

As noted above in Item 2.02, the Company issued a press release announcing financial results for the three months and year ended December 31, 2010. Since issuing the press release, it has come to the Company's attention that two figures in Exhibit 2 of the release were inadvertently transposed. The "Income from continuing operations" and "Net income" figures for the Year Ended December 31, 2010, should have been \$19,015 not \$19,105.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Title</u>
99.1	Press release of Harvard Bioscience, Inc. issued on February 25, 2011.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HARVARD BIOSCIENCE, INC.**

---

(Registrant)

**/s/ THOMAS MCNAUGHTON**

---

**February 25, 2011**

(Date)

---

Thomas McNaughton

*Chief Financial Officer & Principal Accounting Officer*